TGF-ÔRI inhibitor, EW-7197 combination therapy with paclitaxel prolonged the Life Span of Breast Tumor Bearing Mice

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SUN 292-302-Breast & Prostate Cancer
Sunday, June 16, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SUN-302
Yhun Y Sheen*1, Sol J Kim2, Dae-kee Kim2, Seon J Lee2, Min J Kim2, So Y Park2, Sang A Park2 and Jeong S Nam3
1Ewha Women's Univ, Seoul, South Korea, 2Ewha womans university, 3Gacheon University
TGF-β has multifunctional effects on carcinogenesis. In the early stage tumor, TGF-β acts as a tumor suppressor but in later stage of tumor, TGF-β promotes tumor invasiveness and metastasis. TGF-βRI kinase has been the target of anti-metastatic drugs, so we have synthesized new ALK5 inhibitor (EW-7197) and investigated anti-metastatic effects of EW-7197. The treatment of the EW-7197 also inhibited the luciferase activity in the lung of 4T1-Luc cell-orthotopic implanted mouse compared to that of untreated animal. The levels of MMP2 and MMP9 were decreased in the lung and breast tumor of the EW-7197 treated mice. To determine the inhibitory effect of EW-7197 on TGF-β1-induced transcriptional activation, we performed luciferase reporter gene assay in breast cancer cells. EW-7197 effectively blocked TGF-β1-induced luciferase activity in the cells in a dose-dependent manner. TGFß signaling, the phosphorylation of smad2/3 was decreased by EW-7197. TGFß-stimulated mesenchymal markers of epithelial mesenchymal transition (EMT) were inhibited by ALK5 inhibitor concomitant treatment.  And also, EW-7197 showed higher inhibition on cell motility and cell invasion based on wound healing assay or invasion assay. Further, we investigated combination effect of EW-7197 and paclitaxel. To investigate anti-metastatic effect we did experiment on BALB/c-nu/nu MB231-luc cells xenografted mice by treating EW-7197 and paclitaxel. Both EW-7197 alone group and EW-7197 and paclitaxel combination group showed inhibition of metastasis and the expression of lung metastatic markers were inhibited. We experiment on BALB/c-nu/nu MB231 cells xenografted mice for survival analysis. EW-7197 and paclitaxel combination therapy lengthen the life span of mice. In summary, EW-7197 could be effective therapeutic choice for breast cancer metastasis. Also EW-7197 and paclitaxel combination therapy could be more effective than paclitaxel alone therapy for anti-metastatic effect and survival.

Nothing to Disclose: YYS, SJK, DKK, SJL, MJK, SYP, SAP, JSN

*Please take note of The Endocrine Society's News Embargo Policy at

<< Previous Abstract | Next Abstract